Posted by Michael Wonder on 13 Oct 2021
MHRA backs Merck’s MET inhibitor Tepmetko
13 October 2021 - The UK MHRA has conditonally authorised Merck’s MET inhibitor Tepmetko (tepotinib) for the treatment of certain non-small-cell lung cancer patients.
The conditional marketing authorisation opens access to Tepmetko treatment for adult patients with advanced non-small-cell lung cancer harbouring mesenchymal-epithelial transition factor gene exon 14 skipping alterations.
